Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prometheus Biosciences Inc (NQ: RXDX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Prometheus Biosciences Inc

< Previous 1 2 3 4 Next >
Why Shares of Exscientia Jumped on Wednesday
The company may be riding the wave of an AI healthcare boom. 
Via The Motley Fool
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
Why Shares of Ventyx Biosciences Rose Monday
The company has several promising autoimmune therapies. 
Via The Motley Fool
Is Merck Stock a Top Buy Right Now?
The drugmaker is still a work in progress. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Expert Ratings for Prometheus Biosciences
Via Benzinga
3 Innovative Growth Stocks to Buy for Next-Gen Profits
These are the innovative growth stocks for future profits as they represent companies investing significantly in research and development. 
Via InvestorPlace
3 Undervalued Pharma Stocks to Buy for High Total Returns
These are the undervalued pharma stocks to buy as they represent companies investing heavily in research to boost the product pipeline. 
Via InvestorPlace
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
In a rare move to block a large pharma deal, the U.S. 
Via Benzinga
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
Reports the FTC could block Amgen's takeover of Horizon reverberated across biotechs on Tuesday, with HZNP stock's crash leading the way. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Here Are The Best-Performing Industry ETFs And Major Stock Contributors In April
It's a good time to look at how the major U.S. stock industry ETFs performed this month, as April comes to an end. In April, we saw the broader U.S. 
Via Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Merck Makes a Bold Move That Could Transform Its Business
It's a risky deal for Merck, but it could pay off significantly. 
Via The Motley Fool
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review
The major indexes saw modest declines, holding in a range. 
Via Investor's Business Daily
Why Prometheus Biosciences Stock Is Skyrocketing This Week
There's nothing like a big buyout to send a clinical-stage biotech stock soaring higher. 
Via The Motley Fool
Why This Nasdaq Stock Caught Fire This Week
A wave of bargain buying benefited the gene therapy company's shares this week. 
Via The Motley Fool
Why Madrigal Pharmaceuticals Stock Gained 20% This Week
Two key tailwinds fueled a surge in the biotech's share price this week. 
Via The Motley Fool
Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?
Merck's move into immunology is a risky proposition. 
Via The Motley Fool
Why BELLUS Health Stock Is Rocketing Higher Today
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
Shares of its takeover candidate nearly doubled on the news. 
Via Investor's Business Daily
Crude Oil Down 2%; State Street Shares Tumble After Downbeat Results
U.S. stocks traded slightly lower toward the end of trading. The Dow traded down 0.07% to 33,862.05 while the NASDAQ fell 0.24% to 12,093.82. The S&P 500, also fell, dropping, 0.17% to 4,130.78. 
Via Benzinga
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Shares of Prometheus Biosciences Are Soaring Monday
Merck's $10.8 billion buyout offer sent the clinical-stage biotech stock higher. 
Via The Motley Fool
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82. 
Via Benzinga
Gold Drops Below $2,000; Charles Schwab Earnings Top Views
U.S. stocks traded mostly flat midway through trading, following the release of economic data. The Dow traded up 0.01% to 33,890.03 while the NASDAQ fell 0.18% to 12,101.34. The S&P 500, also fell,... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.